SCHEMBL4716872

SCHEMBL4716872

Cc1cccc(C#Cc2ccc(C)s2)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 10/20 0.59
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
KDM4E B2RXH2 1/20 0.54
MEN1 O00255 1/20 0.54
ALDH1A1 P00352 1/20 0.54
TP53 P04637 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
PKM P14618 1/20 0.54
HPGD P15428 1/20 0.54
ALOX15 P16050 1/20 0.54
CYP2C19 P33261 1/20 0.54
THPO P40225 1/20 0.54
KMT2A Q03164 1/20 0.54
GRIN2B Q13224 1/20 0.54
GRM1 Q13255 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18099187 0.77 NPC1 (0.37) NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL4711039 0.76 GRM5 (0.61) GRM5NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL23075939 0.71 GRM5 (0.62) GRM5NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL29355216 0.71 GRM5 (1.00) GRM5NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL103061 0.71 GRM5 (1.00) GRM5NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL1434084 0.70 GRM5 (0.63) GRM5NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL29384255 0.70 GRM5 (0.63) GRM5NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL3274122 0.70 GRM5 (0.60) GRM5NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL16115387 0.70 GRM5 (0.60) GRM5NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL29796588 0.70 GRM5 (0.60) GRM5NPC1RAB9ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP claimed
EP-0998459-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2008-04-23 EP disclosed
US-6656957-B1 Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. NOVARTIS AG (CH) 2003-12-02 US disclosed